These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 36803590)
1. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes. Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia. Krejcik Z; Belickova M; Hrustincova A; Votavova H; Jonasova A; Cermak J; Dyr JE; Merkerova MD Cancer Biomark; 2018; 22(1):101-110. PubMed ID: 29630523 [TBL] [Abstract][Full Text] [Related]
3. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Follo MY; Pellagatti A; Armstrong RN; Ratti S; Mongiorgi S; De Fanti S; Bochicchio MT; Russo D; Gobbi M; Miglino M; Parisi S; Martinelli G; Cavo M; Luiselli D; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L Leukemia; 2019 Sep; 33(9):2276-2290. PubMed ID: 30787430 [TBL] [Abstract][Full Text] [Related]
4. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Bewersdorf JP; Stahl M; Zeidan AM Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770 [TBL] [Abstract][Full Text] [Related]
5. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia. Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579 [No Abstract] [Full Text] [Related]
6. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423 [TBL] [Abstract][Full Text] [Related]
7. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L; Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256 [TBL] [Abstract][Full Text] [Related]
8. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Kenealy M; Hertzberg M; Benson W; Taylor K; Cunningham I; Stevenson W; Hiwase D; Eek R; Zantomio D; Jong S; Wall M; Blombery P; Gerber T; Debrincat M; Zannino D; Seymour JF Haematologica; 2019 Apr; 104(4):700-709. PubMed ID: 30545923 [TBL] [Abstract][Full Text] [Related]
9. Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome. Hrustincova A; Krejcik Z; Kundrat D; Szikszai K; Belickova M; Pecherkova P; Klema J; Vesela J; Hruba M; Cermak J; Hrdinova T; Krijt M; Valka J; Jonasova A; Merkerova MD Cells; 2020 Mar; 9(4):. PubMed ID: 32224889 [TBL] [Abstract][Full Text] [Related]
10. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749 [TBL] [Abstract][Full Text] [Related]
12. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836 [TBL] [Abstract][Full Text] [Related]
13. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178 [TBL] [Abstract][Full Text] [Related]
14. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011 [No Abstract] [Full Text] [Related]
15. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043 [TBL] [Abstract][Full Text] [Related]
16. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086 [TBL] [Abstract][Full Text] [Related]
17. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
18. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Stevens B; Winters A; Gutman JA; Fullerton A; Hemenway G; Schatz D; Miltgen N; Wei Q; Abbasi T; Vali S; Singh NK; Drusbosky L; Cogle CR; Hammes A; Abbott D; Jordan CT; Smith C; Pollyea DA Leuk Res; 2019 Jun; 81():43-49. PubMed ID: 31009835 [TBL] [Abstract][Full Text] [Related]
19. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199 [TBL] [Abstract][Full Text] [Related]
20. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group. Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]